– FRANCE, Bagneux – Genomic Vision (EPA: GV), a biotechnology company today announced the appointment of Emilie Chataignier to the Executive Board and the appointments of Florence Alouch, Mohammed Afshar, and Eric Edery to the Supervisory Board, both effective on July 11, 2022.
These appointments follow the revocation of Remy-Renou as Chair of the Executive Board and the revocation of all the members of the Supervisory Board.
Mrs. Florence Alouch has been appointed as Chair of the Supervisory Board while Aaron Bensimon has been named Chair of the Executive Board.
About Genomic Vision
Genomic Vision is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed for high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in the cancerous cell, for early cancer detection, and for the diagnosis of genetic diseases.
For more information, visit www.genomicvision.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
